[The role of adiponectin and adiponectin receptor 2 in the pathology of fatty liver].
OBJECTIVE
To investigate the role of adiponectin (ADP) and adiponectin receptor 2 (adipoR2) in pathology of fatty liver, and to investigate the effect of Chinese herbal decoction (Qushi Huayu Decoction, QHD) on fatty liver disease.


METHODS
Two experimental fatty liver models were used. One was induced with high-fat diet for ten weeks, and the rats were divided into normal, model and QHD group, the QHD group was administrated with QHD during the last four weeks. The other experimental fatty liver model was induced by subcutaneous injection of carbon tetrachloride (CCl4) in combination with high-fat and low-protein diet for four weeks, and the rats were also divided into normal, model and QHD group, the QHD group was administrated with QHD during the last two weeks. The observation items include: (1) hepatic steatosis (H.E. staining); (2) serum ADP, hepatic triglyceride (TG), free fatty acid (FFA) and adipoR2; (3) correlation among serum ADP content, hepatic TG, FFA and adipoR2.


RESULTS
(1) Serious hepatic steatosis, increased hepatic TG and FFA, decreased serum ADP and hepatic adipoR2 were observed in the two models (P less than 0.01). QHD administration significantly reduced the hepatic TG and FFA, and increased serum ADP and hepatic adipoR2 (P less than 0.01) in these two models. (2) Inverse correlation was observed between hepatic TG, FFA and serum ADP, hepatic adipoR2 in these two models.


CONCLUSIONS
(1) Decreased serum ADP and hepatic adipR2 may play important roles in pathological process of fatty liver. (2) QHD administration increased the serum ADP and hepatic adipoR2.
Li
Hong-shan
HS
Institute of Liver Disease, Shuguang Hospital, Shanghai University of TCM, Shanghai 201203, China.
Feng
Qin
Q
Hu
Yi-yang
YY
Chen
Shao-dong
SD
Peng
Jing-hua
JH
Li
Xue-mei
XM
Xu
Li-li
LL
D052242:Adiponectin / Q000097:blood; D000818:Animals; D002251:Carbon Tetrachloride / Q000008:administration & dosage; D004041:Dietary Fats / Q000008:administration & dosage; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D008517:Phytotherapy; D010946:Plants, Medicinal / Q000737:chemistry; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D054419:Receptors, Adiponectin / Q000378:metabolism*; D014280:Triglycerides / Q000378:metabolism
D052242:Adiponectin; C499920:Adipoq protein, rat; D004041:Dietary Fats; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D005230:Fatty Acids, Nonesterified; D054419:Receptors, Adiponectin; D014280:Triglycerides; C506573:adiponectin receptor 2, rat; C533465:qushi huayu; D002251:Carbon Tetrachloride